1.
Breast Dis
; 42(1): 315-318, 2023.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37807774
RESUMO
ER-/PR+ is a controversial subtype and is not formally recognised as molecular subtype of breast carcinoma. Few studies concluded that this subtype does not exist and is due to technical errors, however, in contrast others consider it to be distinct entity with different response to therapy and clinical outcome. It is also essential to know whether this subtype shows any distinct histomorphological features or prognosis.Therefore, the present two cases of controversial subtype ER-/PR+ breast cancer is being reported with both the cases showing neuroendocrinal differentiation.
Assuntos
Neoplasias da Mama , Humanos , Feminino , Neoplasias da Mama/diagnóstico , Neoplasias da Mama/genética , Neoplasias da Mama/tratamento farmacológico , Receptores de Estrogênio/genética , Prognóstico , Receptores de Progesterona/genética , Receptor ErbB-2 , Biomarcadores Tumorais
2.
Transfus Clin Biol
; 30(2): 175-176, 2023 05.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36228970